<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<title>Monitoring Boundaries for Group Sequential Designs</title>
<style type="text/css">
.underline { text-decoration: underline; }
</style>
<link rel="stylesheet" href="./reveal.js/dist/reveal.css"/>

<link rel="stylesheet" href="./reveal.js/dist/theme/serif.css" id="theme"/>

<link rel="stylesheet" href="./presentation.css"/>
<link rel="stylesheet" href="./reveal.js/plugin/highlight/zenburn.css"/>
<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
</head>
<body>
<div class="reveal">
<div class="slides">
<section id="sec-title-slide">
<h1 class="title">Monitoring Boundaries for Group Sequential Designs</h1><p class="date">Created: 2022-09-19 Mon 23:06</p>
</section>
<section>
<section id="slide-orgab4b9b3">
<h2 id="orgab4b9b3">An example</h2>
<div class="outline-text-2" id="text-orgab4b9b3">
</div>
</section>
<section id="slide-org2b36793">
<h3 id="org2b36793">Background</h3>
<ul>
<li><i>Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously
treated HER2-low advanced breast cancer. N Engl J Med 2022;387:9-20.</i></li>
<li>A Daiichi phase 3, multicenter, randomized, open-label, active-controlled
trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus
treatment of physician’s choice for HER2-low, unresectable and/or metastatic
breast cancer subjects</li>

</ul>
</section>
<section id="slide-org533d3aa">
<h3 id="org533d3aa">Primary and secondary endpoints</h3>
<ul>
<li>Primary
<ul>
<li>PFS in HR+ subjects based on blinded independent central review (BICR)</li>

</ul></li>
<li>Secondary
<ul>
<li>PFS in HR+, based on Investigator assessment</li>
<li>OS in HR+</li>
<li>ORR in HR+</li>
<li>DoR in HR+</li>
<li>PFS, OS, ORR and DoR in all subjects</li>

</ul></li>

</ul>
</section>
<section id="slide-org25c4077">
<h3 id="org25c4077">Interim analyses plan (i)</h3>
<ul>
<li>No interim analysis is planned for PFS</li>
<li>Up to 3 analyses of OS are planned
<ul>
<li>First interim analysis at the time of the final analysis for PFS (provided
PFS is significant), at which point a total of approximately 162 OS events
(49% information fraction) in HR-positive subjects are expected</li>
<li>If the first OS interim analysis is not significant, a second interim
analysis for OS is planned when approximately 233 OS events (70% information
fraction) in HR-positive subjects have been documented</li>
<li>If the second OS interim analysis is not significant, a final analysis for
OS after approximately 333 OS events in HR-positive subjects have been
documented</li>

</ul></li>
<li>A group sequential design, utilizing 3-look <i>Lan-DeMets</i> alpha spending
function with <i>O’Brien-Fleming</i> type stop boundary will be used to construct
the efficacy stopping boundaries overall 2-sided significance level of 0.05</li>

</ul>
</section>
<section id="slide-orgc95d117">
<h3 id="orgc95d117">Interim analyses plan (ii)</h3>

<div id="orgb23a08c" class="figure">
<p><img src="Figures/case1_tb.png" alt="case1_tb.png" height="400px" />
</p>
</div>
</section>
</section>
<section>
<section id="slide-org7a62f99">
<h2 id="org7a62f99">Group sequential design and monitoring boundaries</h2>
<div class="outline-text-2" id="text-org7a62f99">
</div>
</section>
<section id="slide-orgee777aa">
<h3 id="orgee777aa">Objectives</h3>
<ul>
<li>Why do we need monitoring boundaries?</li>
<li>How do Pocock and O'Brien-Fleming boundaries work?</li>
<li>How does an alpha spending function work?</li>

</ul>
</section>
<section id="slide-orgce9e234">
<h3 id="orgce9e234">An Example of RCT</h3>
<ul>
<li>Consider a randomized controlled trial with a continuous endpoint</li>
<li>The <i>goal</i> is to show that the treatment is superior than the control</li>

</ul>
</section>
<section id="slide-org7c3cf31">
<h3 id="org7c3cf31">Group sequential test</h3>
<ul>
<li>A group sequential test monitors a <b>statistic</b> <i>summarizing the difference in
primary responses between the treatment and control groups</i> at <span class="underline">a series of
times</span> during the trial</li>
<li>At interim analyses, if the value of this statistic exceeds some specified
boundary, the trial is stopped and the null hypothesis is rejected</li>
<li>Interim analyses allow the trial to be stopped early with a <i>valid conclusion</i>
<ul>
<li>Participants are not exposed to ineffective or unsafe treatments (ethical)</li>
<li>Assumptions made at the design stage are checked (administrative)</li>
<li>Sample size, time and cost are not wasted (economic)</li>

</ul></li>

</ul>
</section>
<section id="slide-orgc31dd06">
<h3 id="orgc31dd06">A brief history of group sequential test</h3>
<ul>
<li>In the 1920's, <i>group-sequential</i> designs were proposed for industrial
acceptance sampling</li>
<li>In the 1950's, fully sequnetial methods were proposed in the medical field,
but were not well accepted because continuous assessment was often impractical</li>
<li>In 1977, Pocock gave clear guidlines for group sequential designs that attain
type I error and power requirements</li>
<li>In 1979, O'Brien and Fleming proposed group sequential methods that have
conservative stopping boundaries at the early stage of a study</li>

</ul>
</section>
<section id="slide-org93df4dc">
<h3 id="org93df4dc">Information fraction</h3>
<ul>
<li>Defined as the fraction of <i>total information</i> expected at the scheduled end of
the trial</li>
<li>Roughly, \[\mbox{Information Fraction} = {n \mbox{ at the interim analysis}
  \over N \mbox{ at the final analysis}}\]</li>
<li>For survival analysis, \(n\) and \(N\) are the number of events instead of
subjects</li>

</ul>
</section>
<section id="slide-orge624e25">
<h3 id="orge624e25">Maturity</h3>
<ul>
<li>No uniformly accepted definition of what <i>maturity</i> means</li>
<li>Example
<ul>
<li>Maturity is defined as the proportion of patients that had experienced an
event</li>

</ul></li>
<li>Maturity matters more for the estimation of the <i>survival function</i></li>

</ul>
</section>
<section id="slide-org3b66af0">
<h3 id="org3b66af0">Type I error inflation</h3>
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-right" />

<col  class="org-right" />
</colgroup>
<thead>
<tr>
<th scope="col" class="org-right">Number of Interim Analysis</th>
<th scope="col" class="org-right">Type I error (for \(\alpha = 0.05\))</th>
</tr>
</thead>
<tbody>
<tr>
<td class="org-right">1</td>
<td class="org-right">0.083</td>
</tr>

<tr>
<td class="org-right">2</td>
<td class="org-right">0.107</td>
</tr>

<tr>
<td class="org-right">3</td>
<td class="org-right">0.126</td>
</tr>

<tr>
<td class="org-right">10</td>
<td class="org-right">0.193</td>
</tr>
</tbody>
</table>
</section>
<section id="slide-org922c315">
<h3 id="org922c315">Boundaries</h3>
<ul>
<li>Pocock
<ul>
<li>Constant for all analyses: \(c(K)\)</li>
<li>Narrower initially, easier to stop early</li>

</ul></li>
<li>O'Brien-Fleming
<ul>
<li>Narrower boundaries at later analysis (i.e., conservative initially): \(c(K) / \sqrt{k}\)</li>
<li>Similar boundary at the final analysis to the fixed sample test</li>

</ul></li>

</ul>
</section>
<section id="slide-org5f956c9">
<h3 id="org5f956c9">Alpha vs. cumulative alpha (i)</h3>
<ul>
<li>Nominal significance level at the \(k\)th interim analysis
<ul>
<li>\(\alpha_k = \Pr(|Z_k| \geq c_k)\)</li>
<li>Probability of rejecting the null hypothesis at the \(k\)th interim analysis</li>

</ul></li>
<li>The error spent at stage \(k\)
<ul>
<li>\(\pi_k = \Pr(|Z_1| < c_1, \ldots, |Z_k| \geq c_k)\)</li>
<li>Probability of <i>not</i> rejecting \(H_0\) before the \(k\)th interim analysis
<i>and</i> rejecting the null hypothesis at the \(k\)th interim analysis</li>

</ul></li>
<li>Cumulative alpha
<ul>
<li>\(\alpha = \pi_1 + \ldots + \pi_K\)</li>
<li>\(\alpha \neq \alpha_1 + \ldots + \alpha_K\)</li>

</ul></li>

</ul>
</section>
<section id="slide-orgb16322d">
<h3 id="orgb16322d">Alpha vs. cumulative alpha (ii)</h3>
<ul>
<li>Take a study with two interim analyses as an example</li>
<li>OF boundary
<ul>
<li>Cumulative alpha spending: 0.0002592, 0.0071601, 0.0250000</li>
<li><p>
Stage levels (one-sided) : 0.0002592, 0.0070554, 0.0225331
</p>

<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-left" />

<col  class="org-right" />
</colgroup>
<thead>
<tr>
<th scope="col" class="org-left">Analysis</th>
<th scope="col" class="org-left">Probability</th>
<th scope="col" class="org-right">&#xa0;</th>
</tr>
</thead>
<tbody>
<tr>
<td class="org-left">Interim 1</td>
<td class="org-left">Reject \(H_0\) at IA1</td>
<td class="org-right">0.0002592</td>
</tr>

<tr>
<td class="org-left">Interim 2</td>
<td class="org-left">Reject \(H_0\) at IA2</td>
<td class="org-right">0.0070554</td>
</tr>

<tr>
<td class="org-left">&#xa0;</td>
<td class="org-left">Not reject \(H_0\) at IA1 but reject \(H_0\) at IA2</td>
<td class="org-right">0.0071601 - 0.0002592</td>
</tr>

<tr>
<td class="org-left">Final</td>
<td class="org-left">Reject \(H_0\) at FA</td>
<td class="org-right">0.0225331</td>
</tr>

<tr>
<td class="org-left">&#xa0;</td>
<td class="org-left">Not reject \(H_0\) at IA1-2 but reject \(H_0\) at FA</td>
<td class="org-right">0.025 - 0.0071601</td>
</tr>
</tbody>
</table></li>

</ul></li>

</ul>
</section>
<section id="slide-org4e7baec">
<h3 id="org4e7baec">Alpha spending function</h3>
<ul>
<li>Any function can be an alpha spending function if the function satisfies
<ul>
<li>\(\alpha(0)=0\) (value equals \(0\) at the beginning of the study)</li>
<li>\(\alpha(1)=\alpha\) (value equals \(\alpha\) at the final analysis)</li>
<li>Non-decreasing</li>

</ul></li>
<li>A more flexible group sequential procedure that <i>does not require the total
number nor the exact time of the interim analyses to be specified in advance</i></li>

</ul>
</section>
<section id="slide-orge71861a">
<h3 id="orge71861a">Alpha spending function examples</h3>
<ul>
<li>Pocock-type spending function
\[\alpha(t) = \alpha \log \{1 + (e-1)t\} \]</li>
<li>OF-type spending function
\[\alpha(t) = 2 \{1 - \Phi(z_{\alpha/2}/\sqrt{t})\}\]</li>

</ul>
</section>
<section id="slide-org181061e">
<h3 id="org181061e">Reference</h3>
<ul>
<li>Pocock, Stuart J. "Group sequential methods in the design and analysis of
clinical trials." Biometrika 64.2 (1977): 191-199.</li>
<li>O'Brien, Peter C., and Thomas R. Fleming. "A multiple testing procedure for
clinical trials." Biometrics (1979): 549-556.</li>
<li>Jennison, Christopher, and Bruce W. Turnbull. Group sequential methods with
applications to clinical trials. CRC Press, 1999.</li>
<li>Meurer, William J., and Juliana Tolles. "Interim Analyses During Group
Sequential Clinical Trials." JAMA 326.15 (2021): 1524-1525.</li>
<li>Demets, David L., and KK Gordon Lan. "Interim analysis: the alpha spending
function approach." Statistics in medicine 13.13‐14 (1994): 1341-1352.</li>

</ul>
</section>
</section>
<section>
<section id="slide-org11f3be7">
<h2 id="org11f3be7">Case study II</h2>
<div class="outline-text-2" id="text-org11f3be7">
</div>
</section>
<section id="slide-org7cbd201">
<h3 id="org7cbd201">Background</h3>
<ul>
<li><i>Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus
trastuzumab emtansine for breast cancer. N Engl J Med 2022;386:1143-54.</i></li>
<li>A Daiichi phase 3, multicenter, randomized, open-label, active-controlled
study of DS- 8201a, an anti-HER2-antibody drug conjugate, versus
ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or
metastatic breast cancer subjects previously treated with trastuzumab and
taxane</li>

</ul>
</section>
<section id="slide-orge78362d">
<h3 id="orge78362d">Primary and secondary endpoints</h3>
<ul>
<li>Primary
<ul>
<li>PFS</li>

</ul></li>
<li>Secondary
<ul>
<li>OS</li>
<li>ORR</li>
<li>DoR</li>
<li>Clinical benefit rate (CBR)</li>

</ul></li>

</ul>
</section>
<section id="slide-org7b73d6b">
<h3 id="org7b73d6b">Interim analysis plan (i)</h3>
<ul>
<li>An interim analysis of PFS for superiority is planned after approximately 234
PFS events per BICR (70% of target total of 335) have been documented</li>
<li>A group sequential design, utilizing 2-look <i>Haybittle-Peto</i> stop boundary
will be used to construct the efficacy stopping boundaries with an overall
2-sided significance level of 0.05</li>

</ul>
</section>
<section id="slide-org0f10b27">
<h3 id="org0f10b27">Interim analysis plan (ii)</h3>
<ul>
<li>Up to two interim analyses and a final analysis of OS are planned, provided
PFS is statistically significant</li>
<li>The first potential OS analysis will be at the time of the PFS interim
analysis after 96 expected deaths</li>
<li>The second OS interim analysis will be planned after 153 deaths</li>
<li>A final analysis is planned after 250 deaths have been recorded</li>
<li>A group sequential design, utilizing 3-look <i>Lan-DeMets</i> alpha spending function
with <i>O’Brien-Fleming</i> stop boundary, will be used to construct the efficacy
stopping boundaries with an overall 2-sided significance level of 0.05</li>

</ul>
</section>
<section id="slide-org4c6cddb">
<h3 id="org4c6cddb">Interim analysis plan (iii)</h3>

<div id="orgd638be5" class="figure">
<p><img src="Figures/case2_tb.png" alt="case2_tb.png" height="500px" />
</p>
</div>
</section>
</section>
<section>
<section id="slide-org187739a">
<h2 id="org187739a">Case study III</h2>
<div class="outline-text-2" id="text-org187739a">
</div>
</section>
<section id="slide-org9ad5a08">
<h3 id="org9ad5a08">Background</h3>
<ul>
<li><i>Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated
non–small-cell lung cancer. N Engl J Med 2020;383:1711-23</i></li>
<li>An AstraZeneca phase III, double-blind, randomized, placebo-controlled
multi-centre, study to assess the efficacy and safety of AZD9291 versus
placebo, in patients with EGFR+ stage IB-IIIA non-small cell lung carcinoma,
following complete tumour resection with or without adjuvant chemotherapy
(ADAURA)</li>

</ul>
</section>
<section id="slide-orgc1491e6">
<h3 id="orgc1491e6">Primary and secondary endpoint</h3>
<ul>
<li>Primary
<ul>
<li>Disease free survival (DFS)</li>

</ul></li>
<li>Secondary
<ul>
<li>DFS rate at 2, 3 and 5 years</li>
<li>Overall Survival (OS)</li>
<li>OS rate at 5 years</li>

</ul></li>

</ul>
</section>
<section id="slide-orgf26f224">
<h3 id="orgf26f224">Interim analysis plan (i)</h3>
<ul>
<li>The primary analysis was planned to be conducted when approximately 247 DFS
events were observed in the stage II/IIIA population</li>
<li>After a planned meeting in 2019 to assess futility, but not superiority, when
at least 83 disease recurrence events or deaths had occurred in patients with
stage II to IIIA disease, the committee requested assessment of efficacy data
at the next scheduled meeting for safety (April 2020)</li>
<li>On the basis of review of these data, the committee recommended that the
trial be unblinded at a trial level early to complete primary reporting</li>

</ul>
</section>
<section id="slide-org8900c34">
<h3 id="org8900c34">Interim analysis plan (ii)</h3>
<ul>
<li>Two <b>unplanned interim analysis</b> of DFS in the stage II/IIIA population were
conducted at the time of observing 86 DFS events and 156 DFS events
respectively</li>
<li>The corresponding information fractions were 0.35 and 0.63 where the final
number of events would have been 247</li>
<li>The Lan DeMets approach that approximates the O’Brien and Fleming spending
function will be used to maintain an overall 2-sided 5% type I error</li>

</ul>
</section>
<section id="slide-orgc547d20">
<h3 id="orgc547d20">Interim analysis plan (iii)</h3>

<div id="org29ae71f" class="figure">
<p><img src="Figures/case3_tb.png" alt="case3_tb.png" height="400px" />
</p>
</div>
</section>
</section>
<section>
<section id="slide-org55cba63">
<h2 id="org55cba63">Potential limitations</h2>
<div class="outline-text-2" id="text-org55cba63">
</div>
</section>
<section id="slide-org638f8b9">
<h3 id="org638f8b9">Overestimation of the effect size</h3>
<ul>
<li>A trial terminated early for benefit will tend to overestimate the treatment
effect</li>
<li>Extreme p-values are more likely obtained when there is a random "high"
treatment effect</li>
<li>Statistical methods exist for adjusting the overestimation bias
<ul>
<li>Not commonly applied in practice</li>

</ul></li>
<li>It is important to understand the overestimation issue in decision making</li>
<li><i>Zhang, Jenny J., et al. Overestimation of the Effect Size in Group Sequential
Trials. Clinical Cancer Research 18.18 (2012)</i></li>

</ul>
</section>
<section id="slide-org2da8efd">
<h3 id="org2da8efd">Clinical relevance (i)</h3>
<ul>
<li><i>Oncologic Drugs Advisory Committee (ODAC) Meeting, February 9, 2021. BLA
125514 Supplement-089</i></li>
<li>KEYNOTE-522
<ul>
<li>Pembrolizumab vs placebo in combination with chemotherapy in the neoadjuvant
setting and as monotherapy in the adjuvant setting in 1174 patients with
high-risk, early-stage TNBC</li>
<li>The co-primary endpoints are pathologic complete response (pCR) rate and
event-free survival (EFS)</li>

</ul></li>
<li>pCR at IA1
<ul>
<li>Pembrolizumab: \(64.8 (59.9, 69.5)\), \(n = 401\)</li>
<li>Placebo: \(51.2 (44.1, 58.3)\), \(n=201\)</li>
<li>p-value \(0.00055\)</li>

</ul></li>

</ul>
</section>
<section id="slide-org961934c">
<h3 id="org961934c">Clinical relevance (ii)</h3>
<ul>
<li>The FDA's position
<ul>
<li>FDA does not agree that the small pCR rate difference between treatment arms
is clinically meaningful</li>
<li>Interim analyses may overestimate the treatment effect, particularly when
the number of events is small</li>
<li>The data are not sufficiently mature for FDA to consider these interim EFS
results as a reliable estimate of the EFS treatment effect</li>
<li>While FDA agrees that pCR was statistically significant at IA1, FDA
considers pCR at IA3 to be the most accurate estimate of the pCR difference
between treatment arms since this estimate includes all patients who were
randomized</li>

</ul></li>

</ul>
</section>
</section>
</div>
</div>
<script src="./reveal.js/dist/reveal.js"></script>
<script src="./reveal.js/plugin/markdown/markdown.js"></script>
<script src="./reveal.js/plugin/highlight/highlight.js"></script>
<script>
// Full list of configuration options available here:
// https://github.com/hakimel/reveal.js#configuration
Reveal.initialize({

controls: true,
progress: true,
history: false,
center: true,
slideNumber: false,
rollingLinks: false,
keyboard: true,
mouseWheel: false,
fragmentInURL: false,
hashOneBasedIndex: false,
pdfSeparateFragments: true,
overview: true,
margin: 0.10,

transition: 'convex',
transitionSpeed: 'default',

// Plugins with reveal.js 4.x
plugins: [ RevealMarkdown, RevealHighlight ],

// Optional libraries used to extend reveal.js
dependencies: [
]

});
</script>
</body>
</html>
